Amphotericin B

Amphotericin B: Overview

Amphotericin B is a powerful broad-spectrum antifungal agent that has been used for decades to treat severe and life-threatening fungal infections. It is often referred to as the "gold standard" for treating invasive fungal infections due to its efficacy, though its use is often limited by significant toxicity. Amphotericin B is commonly used for infections caused by Candida, Aspergillus, Cryptococcus, and other fungi, especially in critically ill or immunocompromised patients.

---

Mechanism of Action:

Amphotericin B works by binding to ergosterol, a key component of fungal cell membranes. This binding disrupts the cell membrane, creating pores that lead to leakage of intracellular contents (ions, particularly potassium), causing cell death. While highly effective against fungi, this mechanism can also affect human cell membranes, contributing to its toxicity.

---

Formulations of Amphotericin B:

1. Conventional Amphotericin B (Deoxycholate):

   • The original formulation of Amphotericin B.
   • While effective, this formulation is highly toxic, especially to the kidneys, and causes significant infusion-related reactions.

2. Lipid Formulations:

   • These newer formulations encapsulate Amphotericin B in a lipid complex or liposomes, which reduces toxicity while maintaining antifungal efficacy. Common lipid formulations include:
     • Liposomal Amphotericin B (AmBisome)
     • Amphotericin B lipid complex (ABLC, Abelcet)
     • Amphotericin B colloidal dispersion (ABCD, Amphotec)
   • Liposomal Amphotericin B is the most widely used due to its favorable safety profile compared to the other lipid formulations.

---

Spectrum of Activity:

1. Candida species:

   • Amphotericin B has broad activity against most Candida species, including Candida albicans, Candida glabrata, Candida tropicalis, and Candida krusei.
   • It remains effective in many azole-resistant Candida infections.

2. Aspergillus species:

   • Active against Aspergillus fumigatus, Aspergillus flavus, and other species, making it a key option for invasive aspergillosis, especially in critically ill patients.
   • Liposomal Amphotericin B is often used for aspergillosis, particularly when other antifungals, such as voriconazole, are not tolerated or effective.

3. Cryptococcus neoformans:

   • Amphotericin B is the first-line treatment for Cryptococcal meningitis, particularly in patients with HIV/AIDS. It is typically combined with flucytosine during the induction phase of therapy.

4. Zygomycetes (Mucor and Rhizopus species):

   • Amphotericin B is the drug of choice for mucormycosis and zygomycosis, which are aggressive infections that can be life-threatening in immunocompromised patients.

5. Endemic fungi:

   • Active against Histoplasma capsulatum, Blastomyces dermatitidis, and Coccidioides immitis, making it an important treatment for endemic fungal infections such as histoplasmosis, blastomycosis, and coccidioidomycosis.

---

Key Uses:

1. Invasive fungal infections:

   • Amphotericin B is a first-line treatment for severe and invasive fungal infections, including candidiasis, aspergillosis, cryptococcosis, and mucormycosis.
   • Often reserved for patients with life-threatening infections or those who have failed or cannot tolerate other antifungal therapies (e.g., azoles or echinocandins).

2. Cryptococcal meningitis:

   • Amphotericin B (usually liposomal) combined with flucytosine is the preferred induction therapy for cryptococcal meningitis in HIV/AIDS patients. It is then followed by consolidation therapy with fluconazole.

3. Empiric antifungal therapy in neutropenic patients:

   • In patients with prolonged neutropenia at risk for invasive fungal infections, Amphotericin B may be used as part of empiric therapy.

4. Mucormycosis:

   • Amphotericin B is the treatment of choice for mucormycosis, a rare but severe fungal infection, especially in immunocompromised patients such as those with diabetes or undergoing organ transplants.

---

Key Side Effects:

1. Nephrotoxicity:

   • Amphotericin B deoxycholate is notoriously nephrotoxic, with up to 50% of patients experiencing acute kidney injury (AKI) during treatment. It causes direct damage to renal tubular cells and constriction of the renal vasculature, leading to decreased glomerular filtration rate (GFR).
   • Lipid formulations (e.g., liposomal amphotericin B) are significantly less nephrotoxic but still require close monitoring of renal function, especially in patients with pre-existing kidney disease.

2. Infusion-related reactions:

   • Fever, chills, rigors, hypotension, and headache are common reactions during infusion of conventional Amphotericin B, often referred to as "shake and bake" reactions.
   • Pre-medication with acetaminophen, antihistamines, and corticosteroids can help mitigate these reactions.
   • Lipid formulations cause fewer infusion-related side effects but may still provoke mild reactions.

3. Electrolyte imbalances:

   • Hypokalemia and hypomagnesemia are common during treatment with Amphotericin B, due to the drug’s effects on renal tubular cells. These imbalances can lead to cardiac arrhythmias if not monitored and corrected.

4. Anemia:

   • Amphotericin B can suppress erythropoiesis, leading to anemia, particularly with prolonged use.

5. Hepatotoxicity:

   • Though less common than nephrotoxicity, elevated liver enzymes can occur during treatment, especially in combination with other hepatotoxic drugs.

---

Lipid Formulations: A Safer Alternative

1. Liposomal Amphotericin B (AmBisome):

   • This formulation encases Amphotericin B in liposomes, which allows for targeted delivery to fungal cells while reducing exposure to human cells, particularly the kidneys.
   • Liposomal Amphotericin B is associated with fewer side effects, especially reduced nephrotoxicity and infusion reactions, making it the preferred formulation for most patients.

2. Amphotericin B lipid complex (Abelcet) and Amphotericin B colloidal dispersion (Amphotec):

   • These formulations are also used to minimize toxicity but are less frequently employed compared to the liposomal version.

---

Key Notes:

• Monitor renal function: Given the high risk of nephrotoxicity, frequent monitoring of serum creatinine, blood urea nitrogen (BUN), and electrolytes (particularly potassium and magnesium) is critical during treatment.
• Pre-medication: Patients receiving Amphotericin B deoxycholate should be pre-treated with acetaminophen and antihistamines to minimize infusion-related reactions.
• Lipid formulations: Whenever possible, liposomal Amphotericin B should be used to reduce toxicity, especially in patients with pre-existing kidney disease or those at high risk for nephrotoxicity.
• Combination therapy: Amphotericin B is often used in combination with other antifungals, such as flucytosine for cryptococcal meningitis or voriconazole for aspergillosis, to enhance efficacy and reduce resistance.

---

Summary:

• Amphotericin B remains a cornerstone in the treatment of invasive fungal infections, including cryptococcosis, aspergillosis, candidiasis, and mucormycosis, especially in critically ill patients.

• While highly effective, the conventional formulation is limited by significant nephrotoxicity and infusion-related reactions, making lipid formulations such as liposomal Amphotericin B the preferred choice for most patients.

• Close monitoring of renal function, electrolytes, and pre-treatment protocols are essential to safely use Amphotericin B in the clinical setting.

---